Lifeboat Foundation

Researchers have found that people with obstructive sleep apnea have an increased cardiovascular risk due to reduced blood oxygen levels, largely explained by interrupted breathing. Obstructive sleep apnea has long been associated with increased risk of cardiovascular issues, including heart attack, stroke, and death, but the findings from this study, published in the American Journal of Respiratory and Critical Care Medicine, show the mechanism mostly responsible for the link.

“These findings will help better characterize high-risk versions of obstructive sleep apnea,” said Ali Azarbarzin, Ph.D., a study author and director of the Sleep Apnea Health Outcomes Research Group at Brigham and Women’s Hospital and Harvard Medical School, Boston. “We think that including a higher-risk version of obstructive sleep apnea in a randomized clinical trial would hopefully show that treating sleep apnea could help prevent future cardiovascular outcomes.”

Researchers reviewed data from more than 4,500 middle-aged and older adults who participated in the Osteoporotic Fractures in Men Study (MrOS) and the Multi-Ethnic Study of Atherosclerosis (MESA), and sought to identify features of obstructive sleep apnea that could explain why some people were more likely than others to develop cardiovascular disease or related death.

An international team led by investigators at McLean Hospital has analyzed the genes expressed in approximately 575,000 individual cells from the brains of people with and without post-traumatic stress and major depressive disorders (PTSD and MDD), revealing new insights into the mechanisms behind the brain’s stress response in these conditions.

The findings, which are published in The American Journal of Psychiatry, could lead to novel markers of PTSD and MDD and well as new therapeutic targets.

Because studies have implicated the dorsolateral prefrontal cortex (DLPFC) region of the brain in PTSD and MDD, the scientists compared the genes expressed in cells in DLPFC samples collected postmortem from 11 individuals with PTSD, 10 with MDD, and 11 without either of these conditions with a replication dataset half the size. The researchers detected which genes were expressed by which cells—including eight different types of cells—through a technique called single-cell RNA sequencing.

Scientists at the University of Colorado Anschutz Medical Campus have discovered what they believe to be the central mechanism behind cognitive decline associated with normal aging.

“The mechanism involves the mis-regulation of a brain protein known as CaMKII which is crucial for memory and learning,” said the study’s co-senior author Ulli Bayer, PhD, professor of pharmacology at the University of Colorado School of Medicine. “This study directly suggests specific pharmacological treatment strategies.”

The study was published today in the journal ‘Science Signaling.’

Luismmolina/iStock.

However, researchers from Denmark’s Herlev Hospital and UK-based Cardiff University, and the University of Warwick recently published a study that reveals a new superior T-cell which is better at detecting cancer growth and can attack multiple cancer targets.

Crohn’s disease affects four million people worldwide. The condition causes debilitating symptoms such as chronic fatigue, diarrhoea, abdominal pain, weight loss and malnutrition.

Once symptoms develop, Crohn’s is a lifelong condition – and while there are ways to manage symptoms during flare-ups, there’s currently no cure.

The exact causes of Crohn’s disease are unknown and are probably due to a number of complex and overlapping factors – such as genetics, environmental cues (such as smoking) and an immune system that’s overactive in the gut.

An ant species in Australia makes honey that killed some bacterial and fungal infections in the lab, raising hopes that its properties could be used in new drugs.

By Chen Ly

Reduction in blood oxygen levels, largely attributed to blocked airways, emerges as a leading factor.

Researchers have found that people with obstructive sleep apnea have an increased cardiovascular risk due to reduced blood oxygen levels, largely explained by interrupted breathing. Obstructive sleep apnea has long been associated with increased risk of cardiovascular issues, including heart attack, stroke, and death, but the findings from this study, partially supported by the National Institutes of Health and published in the American Journal of Respiratory and Critical Care Medicine, show the mechanism mostly responsible for the link.

“These findings will help better characterize high-risk versions of obstructive sleep apnea,” said Ali Azarbarzin, Ph.D., a study author and director of the Sleep Apnea Health Outcomes Research Group at Brigham and Women’s Hospital and Harvard Medical School, Boston. “We think that including a higher-risk version of obstructive sleep apnea in a randomized clinical trial would hopefully show that treating sleep apnea could help prevent future cardiovascular outcomes.”

Whether episodes of acute kidney injury (AKI) lead to worsening chronic kidney disease (CKD) still is under debate, and some countries now incentivize stricter renal monitoring of patients following hospitalizations for AKI. U.S. researchers prospectively identified 433 adults with known CKD (defined as ≥50% increase in serum creatinine level) and examined whether those episodes contributed to worsening of CKD during 4 years of follow-up. Nearly all the episodes of AKI were stage 1 or 2 (i.e., the ratio of peak to nadir serum creatinine was less than 3).

After adjusting for an extensive set of potentially confounding variables, patients with stage 1 or stage 2 AKI did not have substantial decreases in estimated glomerular filtration rate (eGFR; calculated using creatinine or using cystatin C level) or have substantially accelerated changes in eGFR over time.

These results suggest that in a patient with known CKD, an episode of AKI generally doesn’t affect the subsequent natural history of CKD. Whether more-severe AKI (stage 3 or stage 4) portends worse CKD outcomes could not be determined in this study due to small number of patients with such disease severity.

Nikhil C. Munshi, MD, discusses potential future directions for ciltacabtagene autoleucel and other CAR T-cell therapies in patients with multiple myeloma.